Cosela FDA Approval History
Last updated by Judith Stewart, BPharm on March 4, 2021.
FDA Approved: Yes (First approved February 12, 2021)
Brand name: Cosela
Generic name: trilaciclib
Dosage form: for Injection
Company: G1 Therapeutics, Inc.
Treatment for: Small Cell Lung Cancer Myelopreservation Therapy
Cosela (trilaciclib) is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor myelopreservation therapy for use in patients with small cell lung cancer (SCLC) who are receiving chemotherapy.
- Cosela works to help protect bone marrow (myeloprotection) when administered prior to treatment with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).
- Cosela is administered intravenously as a 30-minute infusion within four hours prior to the start of chemotherapy.
- Common adverse reactions include fatigue, hypocalcemia, hypokalemia, hypophosphatemia, increased aspartate aminotransferase, headache, and pneumonia.
Development Timeline for Cosela
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.